Practical Issues Surrounding Immunotherapy for HNSCC – OncLive
OncLive |
Practical Issues Surrounding Immunotherapy for HNSCC
OncLive Ezra Cohen, MD: Let's talk about a couple of very practical issues. The first is a patient who has had prior cetuximab, and now you're thinking about immunotherapy in the form of an anti-PD-1. Is there a reason to think about that patient any … |
